Ascendis Pharma Past Earnings Performance

Past criteria checks 0/6

Ascendis Pharma's earnings have been declining at an average annual rate of -18.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 73.8% per year.

Key information

-18.5%

Earnings growth rate

-14.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate73.8%
Return on equityn/a
Net Margin-154.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Ascendis Pharma Takes A Big Price Cut On Skytrofa

Sep 05

Ascendis Pharma A/S' (NASDAQ:ASND) Share Price Could Signal Some Risk

Jul 20
Ascendis Pharma A/S' (NASDAQ:ASND) Share Price Could Signal Some Risk

Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S

Apr 05
Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S

Ascendis Pharma's Ambitious Vision 2030

Jan 11

What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You

Dec 21
What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Nov 10
Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Oct 05
Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Jun 27
Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

May 05
Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Feb 18
Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?

Sep 24
Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?

Ascendis Pharma: TransCon CNP Data Coming Q4

Sep 15

Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH

Aug 31

Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa

Aug 11

Ascendis Pharma: Institutional Buying Values Dutch Biotech Best-Now Cap-Gain Prospect

Aug 03

Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money

Jun 10
Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money

Revenue & Expenses Breakdown

How Ascendis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ASND Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24318-490269356
31 Mar 24329-502265378
31 Dec 23267-481264413
30 Sep 23152-602257431
30 Jun 23119-609254417
31 Mar 2378-569240403
31 Dec 2251-583221380
30 Sep 2233-482213337
30 Jun 2219-393192298
31 Mar 2214-446170291
31 Dec 218-384160296
30 Sep 213-416132491
30 Jun 215-458111432
31 Mar 215-41896349
31 Dec 207-41977261
30 Sep 209-3607350
30 Jun 208-26466192
31 Mar 2010-22856140
31 Dec 1913-21848192
30 Sep 1921-17040179
30 Jun 1919-1783770
31 Mar 1916-14231161
31 Dec 1811-13025140
30 Sep 180-13221130
30 Jun 181-13217128
31 Mar 181-14015110
31 Dec 172-12413100
30 Sep 172-1061392
30 Jun 173-911279
31 Mar 174-731270
31 Dec 165-691266
30 Sep 166-641259
30 Jun 166-531050
31 Mar 167-551049
31 Dec 158-33941
30 Sep 159-26836
30 Jun 1510-21831
31 Mar 1512-8823
31 Dec 1414-10620
30 Sep 1417-2415
30 Jun 14200315
31 Mar 14203313
31 Dec 13204213

Quality Earnings: ASND is currently unprofitable.

Growing Profit Margin: ASND is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ASND is unprofitable, and losses have increased over the past 5 years at a rate of 18.5% per year.

Accelerating Growth: Unable to compare ASND's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ASND is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15%).


Return on Equity

High ROE: ASND's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies